Savara (SVRA) said Friday it has launched an Early Access Program for molgramostim, allowing physicians of eligible patients with autoimmune pulmonary alveolar proteinosis to request the investigational inhalation solution in select regions where it is not yet commercially available.
The program has been reviewed and allowed to proceed by the US Food and Drug Administration, and is expected to expand through 2026, Savara said, adding it aims to complete a Biologics License Application submission for molgramostim as a treatment for aPAP to the FDA in H1 2025.
Shares of the company were up nearly 1% in recent Friday premarket activity.
Price: 4.2800, Change: +0.04, Percent Change: +0.94
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.